BioBridge Global Executive and Leadership Team

Norman Kalmin, the Medical Director & Chief Executive Officer & Qualtex Laboratories President at BioBridge Global, directs the overarching clinical and operational strategy for the entire organization. Kalmin oversees the integration of blood and tissue banking services, ensuring that QualTex Laboratories maintains rigorous quality standards for testing and processing. By aligning medical protocols with laboratory output, the Medical Director & Chief Executive Officer & Qualtex Laboratories President optimizes the efficiency of the supply chain for critical biological products. This leadership role involves constant collaboration with the board to expand the reach of GenCure and other subsidiaries. Norman Kalmin drives the long-term vision for the company, focusing on scaling operations to meet the increasing demand for high-quality tissue and blood products. Through this strategic focus, the organization secures its position as a leader in the national healthcare landscape.

Donna Respondek, the Executive Vice President & Chief Financial Officer at BioBridge Global, directs the financial strategy and fiscal health of the organization. Respondek oversees budgeting, capital allocation, and financial reporting for all subsidiaries, including GenCure and the various blood and tissue banks. By implementing robust financial controls, the Executive Vice President & Chief Financial Officer ensures that the company maintains the resources necessary to support its mission-critical operations. This leadership role involves analyzing market trends to guide investment decisions and long-term growth strategies. Donna Respondek collaborates with the board to provide transparency and accountability in all fiscal matters. Through the management of Respondek, the organization secures the financial foundation required to innovate in the advanced therapies space. The Executive Vice President & Chief Financial Officer drives the fiscal discipline that allows the company to expand its impact across the national healthcare market.

John Youngdahl, the Senior Vice President & Chief Financial Officer at BioBridge Global, manages the financial planning and risk management frameworks for the organization. Youngdahl oversees the treasury functions and ensures that the company maintains a healthy balance sheet to support its diverse portfolio of blood and tissue services. By evaluating the financial viability of new projects, the Senior Vice President & Chief Financial Officer provides the data-driven insights necessary for strategic decision-making. This leadership role involves working with the executive team to optimize cost structures and improve operational margins. John Youngdahl facilitates the alignment of financial goals with the broader mission of the company. Through the oversight of Youngdahl, the organization maintains the fiscal stability needed to invest in new technologies and expand its service offerings. The Senior Vice President & Chief Financial Officer drives the financial strategy that supports the long-term growth of the enterprise.

Taylor Audra, the Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood and Tissue at BioBridge Global, manages the daily operational workflows for the South Texas Blood & Tissue Center. Audra coordinates the collection, processing, and distribution of blood products to ensure consistent supply for regional healthcare providers. By streamlining internal logistics, the Chief Operating Officer enhances the responsiveness of the organization to urgent medical needs. Taylor Audra also collaborates with the executive team to implement new technologies that improve donor engagement and product safety. This role requires balancing high-volume operational demands with strict regulatory compliance. Through the leadership of Audra, the organization maintains a reliable infrastructure that supports the broader mission of the company. The Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood and Tissue consistently drives improvements in operational throughput and service delivery.

Geoffrey Kindt, the Interim Senior Vice President, Chief Operating Officer at BioBridge Global, executes the strategic operational initiatives across the corporate portfolio. Kindt monitors the performance of various subsidiaries, ensuring that each unit meets established efficiency benchmarks and quality standards. By analyzing operational data, the Interim Senior Vice President, Chief Operating Officer identifies opportunities for process improvement and resource allocation. This leadership role involves working closely with other C-suite members to align departmental goals with the overarching corporate mission. Geoffrey Kindt facilitates cross-functional communication to ensure that the organization remains agile in a competitive market. Through the oversight of Kindt, the company maintains operational stability while pursuing growth in the tissue and blood banking sectors. The Interim Senior Vice President, Chief Operating Officer drives the implementation of scalable systems that support the long-term sustainability of the entire enterprise.

Mark Fite, the Executive Vice President BioBridge Global, Chief Operating Officer South Texas Blood and Tissue and QualTex Laboratories at BioBridge Global, manages the complex intersection of laboratory testing and blood banking operations. Fite oversees the technical infrastructure at QualTex Laboratories, ensuring that all testing protocols meet the highest industry standards for safety and accuracy. By integrating these laboratory functions with the collection services of South Texas Blood & Tissue, the Executive Vice President BioBridge Global, Chief Operating Officer South Texas Blood and Tissue and QualTex Laboratories optimizes the entire product lifecycle. This role involves managing large-scale operational teams and coordinating with external partners to expand market reach. Mark Fite drives the development of efficient workflows that reduce turnaround times for critical medical testing. Through the leadership of Fite, the organization achieves greater operational synergy and maintains a strong competitive advantage in the healthcare sector.

Adrienne Mendoza, the Chief Operating Officer, BBG Advanced Therapies at BioBridge Global, leads the operational expansion into the specialized field of advanced therapies. Mendoza oversees the development and scaling of manufacturing processes for cell and gene therapy products. By aligning technical capabilities with clinical requirements, the Chief Operating Officer, BBG Advanced Therapies ensures that the organization remains at the forefront of medical innovation. This leadership role involves managing complex partnerships and ensuring that all production facilities adhere to stringent regulatory standards. Adrienne Mendoza coordinates with the research and development teams to translate scientific breakthroughs into viable commercial products. Through the strategic direction of Mendoza, the company strengthens its position in the emerging biotechnology market. The Chief Operating Officer, BBG Advanced Therapies drives the operational excellence required to deliver life-changing therapies to patients across the country.

Rachel Beddard, the Chief Medical Officer at BioBridge Global, directs the clinical governance and medical safety standards for the entire organization. Beddard oversees the medical policies that govern blood and tissue collection, ensuring that all procedures prioritize donor and patient safety. By providing clinical expertise to the executive team, the Chief Medical Officer ensures that the company remains compliant with evolving healthcare regulations. This leadership role involves collaborating with medical directors across the network to standardize care and improve clinical outcomes. Rachel Beddard drives the integration of evidence-based practices into the daily operations of the blood and tissue banks. Through the guidance of Beddard, the organization maintains its reputation for excellence in medical service delivery. The Chief Medical Officer ensures that the company continues to meet the highest standards of clinical integrity while supporting the broader mission of saving lives.

Rachel-Louise Beddard, the Senior Vice President, Chief Medical Officer at BioBridge Global, leads the strategic medical initiatives and clinical research programs. Beddard oversees the development of new medical protocols that enhance the quality and efficacy of tissue and blood products. By fostering relationships with the medical community, the Senior Vice President, Chief Medical Officer ensures that the organization remains aligned with the latest advancements in transfusion medicine. This leadership role involves managing the clinical research portfolio and ensuring that all studies meet rigorous ethical and scientific standards. Rachel-Louise Beddard collaborates with the operations team to implement medical innovations that improve patient care. Through the leadership of Beddard, the company advances its capabilities in the field of regenerative medicine. The Senior Vice President, Chief Medical Officer drives the clinical strategy that supports the organization's commitment to improving health outcomes through scientific excellence.